PANEL AND CONTRACT PRACTICEMinuto, F.; Del Monte, P.; Barreca, A.; Nicolin, A.; Giordano, G. · The Lancet · 1936

Determinants of sensitivity and resistance to fluoropyrimidinesAschele, C.; Guglielmi, A.; Maioli, D.; Sobrero, A.; Rosso, R.; Nicolin, A. · 1990

Oligonucleotide degradation contributes to resistance to antisense compoundsRyte, A; Morelli, S; Mazzei, M; Alama, A; Franco, P; Canti, G F; Nicolin, A · Anti-Cancer Drugs · 1993

Characterization of a monoclonal antibody to L1210 leukaemiaTestorelli, C; Morelli, S; Goldin, A; Nicolin, A · 1982

response of CPA synchronized human breast cancer cells to chemotherapyNicolin, A.; Favoni, R.; Alama, A.; Miglietta, L. · 1987

Combination of photodynamic therapy + immunotherapy + chemotherapy in murine leukiemiaCanti, G.; Calastretti, A.; Bevilacqua, A.; Reddi, E.; Palumbo, G.; Nicolin, A. · Neoplasma · 2010

Fractional-period excitations in continuum periodic systemsNistazakis, H. E.; Porter, Mason A.; Kevrekidis, P. G.; Frantzeskakis, D. J.; Nicolin, A.; Chin, J. K. · Physical Review A · 2006

BAG3 controls angiogenesis through regulation of ERK phosphorylationFalco, A; Festa, M; Basile, A; Rosati, A; Pascale, M; Florenzano, F; Nori, S L; Nicolin, V; Di Benedetto, M; Vecchione, M L; Arra, C; Barbieri, A; De Laurenzi, V; Turco, M C · Oncogene · 2012